Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2021 01/14/2021 01/15/2021 01/19/2021 01/20/2021 Date
227.1(c) 226.12(c) 225.55(c) 231.91(c) 236.7(c) Last
1 809 591 1 728 068 2 242 187 2 044 843 1 608 815 Volume
-0.99% -0.43% -0.25% +2.82% +2.07% Change
More quotes
Financials (USD)
Sales 2020 6 157 M - -
Net income 2020 2 607 M - -
Net cash position 2020 5 869 M - -
P/E ratio 2020 23,9x
Yield 2020 -
Sales 2021 6 930 M - -
Net income 2021 2 669 M - -
Net cash position 2021 9 152 M - -
P/E ratio 2021 23,4x
Yield 2021 -
Capitalization 61 551 M 61 551 M -
EV / Sales 2020 9,04x
EV / Sales 2021 7,56x
Nbr of Employees 3 000
Free-Float 72,2%
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales break down geographically as follows:... 
More about the company
Notations Surperformance© of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
All news about VERTEX PHARMACEUTICALS
01/19Morgan Stanley Adjusts Vertex Pharmaceuticals PT to $251 From $249, Maintains..
MT
01/13VERTEX PHARMACEUTICALS : Abbisko Therapeutics Announces the Appointment of Dr. X..
AQ
01/07RBC Capital Raises Price Targets on Seven Stocks, Lowers Targets on Four, Ahe..
MT
01/07VERTEX PHARMACEUTICALS : to Present at the J.P. Morgan Healthcare Conference on ..
BU
2020Daiwa Securities Starts Vertex Pharmaceuticals at Outperform With $250 Price ..
MT
2020VERTEX PHARMACEUTICALS : Announces New Drug Submission for Investigational Tripl..
AQ
2020VERTEX PHARMACEUTICALS : New-Drug Submission for TRIKAFTA Accepted for Priority ..
MT
2020VERTEX PHARMACEUTICALS : Announces New Drug Submission for Investigational Tripl..
AQ
2020VERTEX PHARMACEUTICALS : Skyhawk Sign Deal to Discover, Develop Treatments for S..
MT
2020VERTEX PHARMACEUTICALS : Announces FDA Approvals of TRIKAFTA, SYMDEKO and KALYDE..
AQ
2020VERTEX PHARMACEUTICALS : Skyhawk and Vertex Establish a Strategic Collaboration ..
BU
2020VERTEX PHARMACEUTICALS : Wins US FDA OK of Trikafta, Symdeko, Kalydeco for Use i..
MT
2020VERTEX PHARMACEUTICALS : Regulators Allow Expanded Use Of Cystic Fibrosis Medici..
DJ
2020VERTEX PHARMACEUTICALS : Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezac..
BU
2020Moderna Receives Price-Target Increase as Oppenheimer Sees COVID-19 Vaccine P..
MT
More news
News in other languages on VERTEX PHARMACEUTICALS
2020VERTEX PHARMACEUTICALS : publication des résultats trimestriels
2020VERTEX PHARMACEUTICALS : Veröffentlichung des Quartalsergebnisses
2020VERTEX PHARMACEUTICALS : präsentiert auf virtuellen Mukoviszidose-Konferenzen in..
2020VERTEX PHARMACEUTICALS : présentera de nouvelles données lors de conférences eur..
2020VERTEX PHARMACEUTICALS : publication des résultats semestriels
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 28
Average target price 286,12 $
Last Close Price 236,70 $
Spread / Highest target 44,9%
Spread / Average Target 20,9%
Spread / Lowest Target -7,06%
EPS Revisions
Managers and Directors
NameTitle
Reshma Kewalramani President, Chief Executive Officer & Director
Jeffrey M. Leiden Executive Chairman
Charles F. Wagner Chief Financial Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS0.15%61 551
GILEAD SCIENCES, INC.16.70%85 227
WUXI APPTEC CO., LTD.14.44%58 153
REGENERON PHARMACEUTICALS12.25%57 234
BEIGENE, LTD.40.41%33 081
GENMAB A/S8.65%28 472